financial results Archives -

Ken Frazier’s final appearance on Merck & Co’s financial results call as chief executive was a muted affair, as

Merck looks at M&A deals as COVID hits sales in Q1

https://pharmaphorum.com/news/merck-looks-at-ma-deals-as-covid-hits-sales-in-q1/

Boehringer Ingelheim, Biberach, Germany, February 2007

News/ News/ R&D

COVID-19 drives Boehringer’s R&D spend to record level in 2020

Phil Taylor antibody, Boehringer Ingelheim, coronavirus, COVID-19, financial results 0 Comment

Boehringer Ingelheim invested €3.7 billion on R&D last year, the highest spend in its history, as it mobilised

COVID-19 drives Boehringer’s R&D spend to record level in 2020

https://pharmaphorum.com/news/covid-19-drives-boehringers-rd-spend-to-record-level-in-2020/

News/ News/ Sales and Marketing

Vaccine sales recover at GSK in Q3, but lockdown fears weigh on shares

Phil Taylor coronavirus, coronavirus vaccine, COVID-19, financial results, GlaxoSmithKline, Shingrix, Trelegy 0 Comment

GlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the

Vaccine sales recover at GSK in Q3, but lockdown fears weigh on shares

https://pharmaphorum.com/news/vaccine-sales-recover-at-gsk-in-q3-but-lockdown-fears-weigh-on-shares/

News/ News

COVID-19 bites into Pfizer’s Q3, but biopharma revenues rise

George Underwood financial results, Pfizer, Q3 0 Comment

Pfizer is one of the front-runners in the race to approve a COVID-19 vaccine but the US company

COVID-19 bites into Pfizer’s Q3, but biopharma revenues rise

https://pharmaphorum.com/news/covid-bites-into-pfizers-q3-but-biopharma-revenues-rise/

News/ News/ Sales and Marketing

GSK starts 2020 on a high, but warns of tougher times ahead

Phil Taylor coronavirus, financial results, GlaxoSmithKline, Shingrix, Zejula 0 Comment

GlaxoSmithKline saw its sales surge in the first three months of the year, with the coronavirus pandemic giving

GSK starts 2020 on a high, but warns of tougher times ahead

https://pharmaphorum.com/news/gsk-starts-2020-on-a-high-but-warns-of-tougher-times-ahead/

News/ News/ R&D

Pfizer will start COVID-19 vaccine trial in US next week

Phil Taylor coronavirus, coronavirus vaccine, financial results, Pfizer 0 Comment

Pfizer is preparing to start clinical trials of its COVID-19 candidate in the US next week, and says

Pfizer will start COVID-19 vaccine trial in US next week

https://pharmaphorum.com/news/pfizer-will-start-coronavirus-vaccine-trial-in-us-next-week/

News/ News/ Sales and Marketing

Lilly raises 2020 earnings forecast on pandemic stockpiling

Phil Taylor Basaglar, coronavirus, Eli Lilly, financial results, Humalog, Taltz, Trulicity 0 Comment

Stockpiling of drugs for chronic diseases like diabetes during the coronavirus pandemic lifted Eli Lilly’s first-quarter results, and

Lilly raises 2020 earnings forecast on pandemic stockpiling

https://pharmaphorum.com/news/lilly-raises-2020-earnings-forecast-on-pandemic-stockpiling/

News/ News/ Sales and Marketing

Ozempic acceleration buoys Novo Nordisk, and threatens Lilly

Phil Taylor Diabetes, Eli Lilly, financial results, Novo Nordisk, Ozempic, Rybelsus, Saxenda, Trulicity 0 Comment

Solid growth for Novo Nordisk’s weekly GLP-1 agonist Ozempic in the fourth quarter helped the Danish drugmaker beat

Ozempic acceleration buoys Novo Nordisk, and threatens Lilly

https://pharmaphorum.com/news/ozempic-acceleration-buoys-novo-nordisk-and-threatens-lilly/

News/ News/ Sales and Marketing/ Top stories

Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge

Phil Taylor Diabetes, Eli Lilly, financial results, Novo Nordisk, Ozempic, Rybelsus, Trulicity 0 Comment

Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but

Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge

https://pharmaphorum.com/news/lillys-diabetes-med-trulicity-shrugs-off-novo-nordisk-challenge/

Trending

financial results

Login